Early Detection of COVID-19 Using Breath Analysis

Early Detection of the 2019 Novel Coronavirus (SARS-CoV-2) Using Breath Analysis: First Cross-Sectional Study

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04602884

Acronym

COVID-19

Enrollment

Registered

2020-10-26

Start date

2020-09-22

Completion date

2021-12-30

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

EARLY DETECTION OF COVID-19 USING BREATH ANALYSIS- FIRST CROSS-SECTIONAL STUDY

Detailed description

Primary objective- to identify and evaluate a set of biomarkers that represent both the genetic expression of the virus itself (SARS-CoV-2) and the metabolic activity of the immune system's response to the virus.

Interventions

DIAGNOSTIC_TESTBreath biopsy sampling using the ReCIVA Breath Sampler

Breath biopsy sampling using the ReCIVA Breath Sampler

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 18 to 55 years at the time of consent * Positive results for SARS-CoV-2 * Capable of understanding written and/or spoken language * Able to provide informed consent

Exclusion criteria

* Age under 18 years old * (Anticipated) inability to complete breath sampling procedure due to e.g. hyper- or hypoventilation, respiratory failure, or claustrophobia when wearing the sampling mask * Persons under guardianship or deprived of liberty * Patients with the following diseases: Cancer, Asthma, Chronic Respiratory Disease * Pregnant women * Treated with antiviral drugs upon admission or during hospitalization * Novices and soldiers in initial training

Design outcomes

Primary

Measure	Time frame	Description
Correlation between Volatile Organic Compounds pattern and COVID-19 detection status.	Through the study completion, up to 3 months.	Correlation between the set of Volatile Organic Compounds found in breath biopsy and COVID-19 detection presence in a swab test.

Secondary

Measure	Time frame	Description
Correlation between Volatile Organic Compounds pattern and time from COVID-19 detection.	Through the study completion, up to 3 months.	Correlation between the set of Volatile Organic Compounds found in breath biopsy and time since COVID-19 detected in a swab test.
Correlation between the set of Volatile Organic Compounds found in breath biopsy and disease intensity.	Through the study completion, up to 3 months.	Correlation between the set of Volatile Organic Compounds found in breath biopsy and intensity of COVID-19 detected in a swab test.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026